trial
as of 2026-07-01A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
NCTId NCT02566759
at a glance
Phase 1 · Terminated
Enrollment 110 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2016-06-09
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Terminated
Enrollment
110 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2015-09-23
Primary completion
2016-06-09
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Neurocrine BiosciencesLead Sponsor
TakedaCollaborator
Sites
0 total
Facts & assertions
4 sourced
Enrollment
110
Phase
PHASE1
Primary Completion Date
2016-06-09
Status
TERMINATED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
company
indication